Pegvisomant blocks the action of growth hormone at the growth hormone receptor to reduce the production of IGF-1 [REF].
Long-term treatment studies with pegvisomant as a monotherapy have shown it be safe,[REF] and to date is the most effective treatment of acromegaly as both a monotherapy and in combination with somatostatin analogues [REF].